Latest Peyronie's disease Stories
MALVERN, Pa., Jan. 3, 2013 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL) today announced that executive management will participate in the J.P. Morgan 2013 Healthcare Conference to be held January 7-10, 2013 at the Westin St. Francis Hotel in San Francisco, CA. Mr. Adrian Adams, Chief Executive Officer and President, is scheduled to present an overview of the Company and its product pipeline at 4:00 p.m. PT on Wednesday, January 9, 2013. (Logo:...
MALVERN, Pa., Dec. 27, 2012 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a specialty biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing and granted standard review status to its supplemental Biologics License Application (sBLA) for XIAFLEX(®) (collagenase clostridium histolyticum or CCH), a novel, in-office biologic therapy for the potential treatment of Peyronie's disease (PD). Under the Prescription...
LYNBROOK, N.Y., Dec. 13, 2012 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX in the U.S. and XIAPEX® in Europe and Eurasia, today announced top-line 30-day data from the Phase Ib study of XIAFLEX for the potential treatment of adult patients with edematous fibrosclerotic panniculopathy (EFP), commonly known as cellulite, which is being conducted by BioSpecifics'...
MALVERN, Pa., Dec. 13, 2012 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a specialty biopharmaceutical company, today announced top-line Day 30 data for collagenase clostridium histolyticum or CCH for the potential treatment, if approved by the U.S. Food and Drug Administration (FDA), of adult patients with edematous fibrosclerotic panniculopathy (EFP), commonly known as cellulite. The phase Ib study is a single site, open-label dose-escalation study that...
NEW YORK, Dec. 10, 2012 /PRNewswire/ -- RetailInvestorConferences.com is pleased to announce that BioSpecifics Technologies Corp.'s (NASDAQ: BSTC) December 6th RetailInvestorConferences.com presentation is now available for on-demand viewing. BioSpecifics is a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX® in the U.S. and XIAPEX® in Europe and Eurasia. LINK: www.retailinvestorconferences.com > red "register/ watch event...
MALVERN, Pa., Dec. 7, 2012 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (Nasdaq: AUXL) today announced that executive management will participate in the Oppenheimer Annual Growth Conference to be held December 12-13, 2012 at the Waldorf Astoria Hotel in New York City. Mr. Adrian Adams, Chief Executive Officer and President, is scheduled to present an overview of the Company and its product pipeline at 2:10 p.m. ET on Thursday, December 13, 2012. (Photo:...
NEW YORK, Dec. 4, 2012 /PRNewswire/ -- RetailInvestorConferences.com is pleased to announce that BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX® in the U.S. and XIAPEX® in Europe and Eurasia, will present at RetailInvestorConferences.com. BioSpecifics' President Tom L. Wegman will be speaking directly to investors. DATE: December 6, 2012 TIME: 3:00 PM EST LINK:...
LYNBROOK, N.Y., Nov. 15, 2012 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX® in the U.S. and XIAPEX® in Europe and Eurasia, today announced that its Board of Directors has reauthorized the stock repurchase program under which BioSpecifics is authorized to repurchase up to $2 million of its outstanding common stock. This decision reflects BioSpecifics' continued...
LYNBROOK, N.Y., Nov. 8, 2012 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX® in the U.S. and XIAPEX® in Europe and Eurasia, today announced its financial results for the third quarter ended September 30, 2012 and provided a corporate update. "We are very happy with the ongoing clinical development progress for our XIAFLEX pipeline, including the recent submission...
LYNBROOK, N.Y., Nov. 7, 2012 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX® in the U.S., today announced the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) for XIAFLEX for the potential treatment of Peyronie's disease by BioSpecifics' partner Auxilium Pharmaceuticals, Inc. (Auxilium). If approved...
